Evidence map›Paper›PMID 30375494›Full record

ReviewNature reviews. Cardiology2018

Safety and efficacy of statin therapy.

Bhavin B Adhyaru, Terry A Jacobson

2 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 228 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
228citing papers in PubMed, 15 pooled it
30.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04862962 completedstarted 2021, after this paper: background citation

Retrospective Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin / Ezetimibe as a Treatment for Patients With Dyslipidaemia in Usual Medical Practice.

Ran2021Enrolled120Registered outcomes5Posted comparisons0ConditionsDyslipidemiasArmsRosuvastatin 10 or 20mg /Ezetimibe 10 mg Fixed Dose
PMID 25915909PMID 17317370PMID 19436657PMID 21267417PMID 15531000PMID 24603993PMID 22442638PMID 21346920PMID 17162426other papers from this trial
Open the trial in the graph
NCT06551298 nanot yet recruitingstarted 2024, after this paper: background citation

Multi Center Clinical Study on the Lipid-lowering Efficacy and Safety of Menggongzi Tibetan Tea Special Drink

Ran2024Enrolled129Registered outcomes2Posted comparisons0ConditionsHyperlipidemiasArmsAtorvastatin Calcium 20Mg Tab, Low fat diet, Menggongzi Tibetan Tea Special Drink
PMID 36858834PMID 30653440PMID 8531308PMID 38865662PMID 38399268PMID 35945174PMID 30700139PMID 31504418PMID 32818824PMID 34472586PMID 35525255PMID 34778156other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

228 citing papers in PubMed, 15 syntheses or guidelines pooled it, 418 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Statins reduce mortality in patients with COVID-19: an updated meta-analysis of 147 824 patients.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021
    Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Trial
  17. Trial
  18. Efficacy of Atorvastatin Against Venous Thromboembolism After Total Hip Arthroplasty.Journal of musculoskeletal & neuronal interactions · 2025
    Trial
  19. Trial
  20. Trial

168 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Bhavin B AdhyaruDivision of General Internal Medicine & Geriatrics, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA. badhyar@emory.edu.
Terry A JacobsonDivision of General Internal Medicine & Geriatrics, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA. tjaco02@emory.edu.
Emory University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 2013 ACC/AHA guidelines on blood cholesterol management were a major shift in the delineation of the main patient groups that could benefit from statin therapy and emphasized the use of higher-intensity statin therapies. In 2016, an expert consensus panel from the ACC recommended the use of nonstatin therapies (ezetimibe and PCSK9 inhibitors) in addition to maximally tolerated statin therapy in individuals whose LDL-cholesterol and non-HDL-cholesterol levels remained above certain thresholds after statin treatment. Given the substantial benefits of statin therapies in both primary and secondary prevention of cardiovascular disease, their long-term safety has become a concern. The potential harmful effects of statin therapy on muscle and liver have been known for some time, but new concerns have emerged regarding the risk of new-onset diabetes mellitus, cognitive impairment and haemorrhagic stroke associated with the use of statins and the risks of achieving very low levels of LDL cholesterol. The increased media attention on the adverse events associated with statins has unfortunately led to statin therapy discontinuation, nonadherence to therapy or concerns about initiating statin therapy. In this Review, we explore the safety of statin therapy in light of the latest evidence and provide clinicians with reassurance about the safety of statins. Overwhelming evidence suggests that the benefits of statin therapy far outweigh any real or perceived risks.

Indexed as

BiomarkersCardiovascular DiseasesDyslipidemiasHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLipidsPatient SafetyPractice Guidelines as TopicRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeBiomarkersHydroxymethylglutaryl-CoA Reductase InhibitorsLipids

Identifiers

PMID30375494
OpenAlexW2898998405

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.